{"id":"je-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated Japanese encephalitis virus or viral antigens that trigger both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and neutralize the virus upon natural exposure, preventing infection or reducing disease severity. The vaccine is typically administered as a series of doses to establish protective immunity.","oneSentence":"JE vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:34.435Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Japanese encephalitis in endemic regions"}]},"trialDetails":[{"nctId":"NCT03920111","phase":"NA","title":"Flavivirus Cross-priming Potential of IMOJEV","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2021-04-16","conditions":"Japanese Encephalitis","enrollment":19},{"nctId":"NCT06678373","phase":"PHASE4","title":"Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Liaoning Chengda Biotechnology CO., LTD","startDate":"2024-11-14","conditions":"Japanese Encephalitis","enrollment":250},{"nctId":"NCT02545517","phase":"PHASE3","title":"A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-05","conditions":"Virus Diseases, Rabies","enrollment":459},{"nctId":"NCT00594958","phase":"PHASE3","title":"Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2006-09","conditions":"Japanese Encephalitis","enrollment":639},{"nctId":"NCT00605085","phase":"PHASE3","title":"Safety and Tolerability of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-10","conditions":"Japanese Encephalitis","enrollment":2675},{"nctId":"NCT00604708","phase":"PHASE3","title":"Immunogenicity Study of the Japanese Encephalitis Vaccine IC51","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2005-09","conditions":"Japanese Encephalitis","enrollment":867},{"nctId":"NCT06027801","phase":"NA","title":"Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2023-09-06","conditions":"Iron Deficiency Anemia","enrollment":150},{"nctId":"NCT05568953","phase":"PHASE2","title":"An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity","status":"UNKNOWN","sponsor":"Singapore General Hospital","startDate":"2022-09-28","conditions":"Infectious Disease, Yellow Fever, Japanese Encephalitis","enrollment":70},{"nctId":"NCT05545683","phase":"PHASE3","title":"Safety and Immunogenicity of Inactivated Heterologous Booster Vaccination","status":"WITHDRAWN","sponsor":"Centro de Estudios en Infectogía Pediatrica","startDate":"2022-12-01","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04817917","phase":"PHASE4","title":"Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2021-03-01","conditions":"Japanese Encephalitis, Vaccine Preventable Disease, Vaccine Reaction","enrollment":712},{"nctId":"NCT01190228","phase":"PHASE3","title":"Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-08-25","conditions":"Japanese Encephalitis, Varicella","enrollment":454},{"nctId":"NCT01943825","phase":"PHASE2","title":"Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-11-05","conditions":"Dengue, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":90},{"nctId":"NCT02514746","phase":"PHASE4","title":"Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose","status":"COMPLETED","sponsor":"PATH","startDate":"2015-07-30","conditions":"Encephalitis, Japanese","enrollment":561},{"nctId":"NCT02880865","phase":"PHASE4","title":"Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2016-10-13","conditions":"Encephalitis, Japanese, Measles, Mumps","enrollment":628},{"nctId":"NCT01047839","phase":"PHASE3","title":"Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-01","conditions":"Encephalitis","enrollment":100},{"nctId":"NCT00463476","phase":"PHASE4","title":"Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2007-07-09","conditions":"Japanese Encephalitis","enrollment":305},{"nctId":"NCT00249769","phase":"PHASE3","title":"Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2005-11-21","conditions":"Encephalitis, Japanese B","enrollment":600},{"nctId":"NCT00463684","phase":"PHASE4","title":"Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age","status":"COMPLETED","sponsor":"PATH","startDate":"2007-07-07","conditions":"Japanese Encephalitis","enrollment":278},{"nctId":"NCT03282370","phase":"PHASE3","title":"Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam","status":"COMPLETED","sponsor":"National Institute of Hygiene and Epidemiology, Vietnam","startDate":"2017-09-30","conditions":"Japanese Encephalitis","enrollment":655},{"nctId":"NCT03519568","phase":"PHASE4","title":"Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine","status":"UNKNOWN","sponsor":"Shandong Province Centers for Disease Control and Prevention","startDate":"2018-03-01","conditions":"Enterovirus 71 Inactivated Vaccine, HFMD","enrollment":1944},{"nctId":"NCT00322049","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2004-02","conditions":"Dengue","enrollment":51},{"nctId":"NCT01001988","phase":"PHASE3","title":"Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-08-07","conditions":"Encephalitis, Japanese Encephalitis","enrollment":596},{"nctId":"NCT02526550","phase":"PHASE4","title":"Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX","status":"COMPLETED","sponsor":"Siriraj Hospital","startDate":"2014-06","conditions":"Encephalitis","enrollment":50},{"nctId":"NCT01635816","phase":"PHASE4","title":"Immunogenicity of SA 14-14-2 JE Vaccine","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2012-05","conditions":"Healthy Infants","enrollment":1000},{"nctId":"NCT02643433","phase":"PHASE4","title":"Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2015-08","conditions":"Measles, Rubella, Japanese Encephalitis","enrollment":1043},{"nctId":"NCT01981967","phase":"PHASE4","title":"Post-licensure Safety Study of IMOJEV® in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-11","conditions":"Japanese Encephalitis","enrollment":10000},{"nctId":"NCT02602652","phase":"NA","title":"Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2013-12","conditions":"Japanese Encephalitis","enrollment":50},{"nctId":"NCT00735644","phase":"PHASE3","title":"Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-08","conditions":"Japanese Encephalitis, Hepatitis A","enrollment":1200},{"nctId":"NCT01335412","phase":"","title":"Safety Surveillance After Immunization With IXIARO","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2011-03","conditions":"Japanese Encephalitis","enrollment":20000},{"nctId":"NCT00740155","phase":"PHASE2","title":"Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-08","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":154},{"nctId":"NCT01662440","phase":"PHASE3","title":"Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-08","conditions":"Rabies, Japanese Encephalitis","enrollment":661},{"nctId":"NCT01408537","phase":"PHASE3","title":"Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2010-05","conditions":"Encephalitis, Japanese B","enrollment":152},{"nctId":"NCT00412516","phase":"PHASE3","title":"Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2006-12","conditions":"Encephalitis, Japanese B","enrollment":519},{"nctId":"NCT00621764","phase":"PHASE2","title":"Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-03","conditions":"Japanese Encephalitis, Hepatitis A","enrollment":300},{"nctId":"NCT01188343","phase":"PHASE3","title":"Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-08","conditions":"Japanese Encephalitis, Measles, Mumps","enrollment":542},{"nctId":"NCT01466387","phase":"PHASE3","title":"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-11","conditions":"Meningococcal Disease, Meningococcal Meningitis, Typhoid","enrollment":552},{"nctId":"NCT01815073","phase":"PHASE4","title":"Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine","status":"COMPLETED","sponsor":"Changchun Keygen Biological Products Co., Ltd.","startDate":"2013-03","conditions":"Japanese Encephalitis, Chickenpox","enrollment":497},{"nctId":"NCT00384670","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2003-08","conditions":"Dengue Fever","enrollment":7},{"nctId":"NCT01150942","phase":"PHASE3","title":"Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2010-08","conditions":"Japanese Encephalitis","enrollment":205},{"nctId":"NCT01092507","phase":"PHASE3","title":"A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-03","conditions":"Encephalitis, Japanese Encephalitis","enrollment":300},{"nctId":"NCT01954810","phase":"PHASE4","title":"Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2013-10","conditions":"Japanese Encephalitis","enrollment":88},{"nctId":"NCT01559831","phase":"PHASE1","title":"Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination","status":"WITHDRAWN","sponsor":"Valneva Austria GmbH","startDate":"2012-06","conditions":"Japanese Encephalitis","enrollment":""},{"nctId":"NCT00314132","phase":"PHASE3","title":"Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-10","conditions":"Encephalitis, Japanese Encephalitis","enrollment":2004},{"nctId":"NCT00314145","phase":"PHASE3","title":"A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-11","conditions":"Japanese Encephalitis","enrollment":820},{"nctId":"NCT00981630","phase":"PHASE2","title":"Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-11","conditions":"Japanese Encephalitis","enrollment":128},{"nctId":"NCT00982137","phase":"PHASE2","title":"Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-07","conditions":"Japanese Encephalitis, Yellow Fever","enrollment":108},{"nctId":"NCT00441259","phase":"PHASE2","title":"Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-01","conditions":"Japanese Encephalitis","enrollment":96},{"nctId":"NCT00319592","phase":"PHASE2","title":"A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-05","conditions":"Japanese Encephalitis","enrollment":60},{"nctId":"NCT00981175","phase":"PHASE2","title":"A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-04","conditions":"Encephalitis, Japanese Encephalitis","enrollment":202},{"nctId":"NCT01158599","phase":"PHASE4","title":"This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-06","conditions":"Japanese Encephalitis","enrollment":200},{"nctId":"NCT01386827","phase":"PHASE3","title":"Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2008-01","conditions":"Japanese Encephalitis","enrollment":120},{"nctId":"NCT00694460","phase":"PHASE2","title":"Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-08","conditions":"Rabies, Japanese Encephalitis, Pre-Exposure Prophylaxis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":321,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JE vaccine","genericName":"JE vaccine","companyName":"Boryung Pharmaceutical Co., Ltd","companyId":"boryung-pharmaceutical-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"JE vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus. Used for Prevention of Japanese encephalitis in endemic regions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}